Living Cell Technologies Limited (LVCLF)
USD 0.0
(-62.5%)
USD 0.0
(-62.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -2.07 Million AUD | 2.44% |
| 2023 | -2.12 Million AUD | 9.94% |
| 2022 | -2.36 Million AUD | -3.54% |
| 2021 | -2.28 Million AUD | 27.8% |
| 2020 | -3.16 Million AUD | 24.01% |
| 2019 | -4.16 Million AUD | 2.54% |
| 2018 | -4.27 Million AUD | 18.69% |
| 2017 | -5.25 Million AUD | -30.13% |
| 2016 | -4.03 Million AUD | 42.63% |
| 2015 | -7.03 Million AUD | -3.99% |
| 2014 | -6.76 Million AUD | -127.96% |
| 2013 | -2.96 Million AUD | -152.17% |
| 2012 | 5.68 Million AUD | 163.8% |
| 2011 | -8.91 Million AUD | -26.42% |
| 2010 | -7.05 Million AUD | 9.67% |
| 2009 | -7.8 Million AUD | -18.45% |
| 2008 | -6.59 Million AUD | -15.78% |
| 2007 | -5.69 Million AUD | 16.49% |
| 2006 | -6.81 Million AUD | -11.96% |
| 2005 | -6.08 Million AUD | -185.28% |
| 2004 | -2.13 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -2.2 Million AUD | -3.34% |
| 2024 Q2 | -1.5 Million AUD | -161.29% |
| 2024 Q3 | -313.49 Thousand AUD | 79.12% |
| 2024 Q4 | -313.49 Thousand AUD | 0.0% |
| 2024 Q1 | -574.54 Thousand AUD | 29.83% |
| 2023 Q1 | -465.35 Thousand AUD | 62.94% |
| 2023 Q3 | -168.43 Thousand AUD | 87.15% |
| 2023 Q4 | -818.76 Thousand AUD | -386.09% |
| 2023 Q2 | -1.31 Million AUD | -181.66% |
| 2023 FY | -2.12 Million AUD | 9.94% |
| 2022 Q1 | -302.9 Thousand AUD | 72.93% |
| 2022 FY | -2.36 Million AUD | -3.54% |
| 2022 Q2 | -1.12 Million AUD | -269.85% |
| 2022 Q4 | -1.25 Million AUD | -194.12% |
| 2022 Q3 | -426.96 Thousand AUD | 61.89% |
| 2021 FY | -2.28 Million AUD | 27.8% |
| 2021 Q2 | -1.15 Million AUD | -308.76% |
| 2021 Q1 | -283.76 Thousand AUD | 79.91% |
| 2021 Q3 | -386.75 Thousand AUD | 66.66% |
| 2021 Q4 | -1.11 Million AUD | -189.31% |
| 2020 FY | -3.16 Million AUD | 24.01% |
| 2020 Q3 | -400.75 Thousand AUD | 76.88% |
| 2020 Q2 | -1.73 Million AUD | -237.0% |
| 2020 Q4 | -1.41 Million AUD | -252.52% |
| 2020 Q1 | -514.29 Thousand AUD | 33.59% |
| 2019 FY | -4.16 Million AUD | 2.54% |
| 2019 Q1 | -505.24 Thousand AUD | 25.98% |
| 2019 Q4 | -774.36 Thousand AUD | 0.0% |
| 2019 Q2 | -1.8 Million AUD | -257.39% |
| 2019 Q3 | -774.36 Thousand AUD | 57.12% |
| 2018 Q1 | -662.25 Thousand AUD | -7.14% |
| 2018 FY | -4.27 Million AUD | 18.69% |
| 2018 Q4 | -682.56 Thousand AUD | 0.0% |
| 2018 Q3 | -682.56 Thousand AUD | -3.07% |
| 2018 Q2 | -662.25 Thousand AUD | 0.0% |
| 2017 Q3 | -618.09 Thousand AUD | 42.41% |
| 2017 FY | -5.25 Million AUD | -30.13% |
| 2017 Q4 | -618.09 Thousand AUD | 0.0% |
| 2017 Q1 | -1.07 Million AUD | -170.65% |
| 2017 Q2 | -1.07 Million AUD | 0.0% |
| 2016 Q2 | -815.51 Thousand AUD | 0.0% |
| 2016 FY | -4.03 Million AUD | 42.63% |
| 2016 Q4 | -396.57 Thousand AUD | 0.0% |
| 2016 Q3 | -396.57 Thousand AUD | 51.37% |
| 2016 Q1 | -815.51 Thousand AUD | 3.65% |
| 2015 Q4 | -846.41 Thousand AUD | 0.0% |
| 2015 FY | -7.03 Million AUD | -3.99% |
| 2015 Q2 | -681.99 Thousand AUD | 0.0% |
| 2015 Q3 | -846.41 Thousand AUD | -24.11% |
| 2015 Q1 | -681.99 Thousand AUD | -147.8% |
| 2014 Q3 | -275.22 Thousand AUD | 20.7% |
| 2014 Q2 | -347.05 Thousand AUD | 0.0% |
| 2014 Q1 | -347.05 Thousand AUD | -173.65% |
| 2014 FY | -6.76 Million AUD | -127.96% |
| 2014 Q4 | -275.22 Thousand AUD | 0.0% |
| 2013 Q3 | -126.82 Thousand AUD | 0.0% |
| 2013 FY | -2.96 Million AUD | -152.17% |
| 2013 Q4 | -126.82 Thousand AUD | 0.0% |
| 2012 FY | 5.68 Million AUD | 163.8% |
| 2011 FY | -8.91 Million AUD | -26.42% |
| 2010 FY | -7.05 Million AUD | 9.67% |
| 2009 FY | -7.8 Million AUD | -18.45% |
| 2008 FY | -6.59 Million AUD | -15.78% |
| 2007 FY | -5.69 Million AUD | 16.49% |
| 2006 FY | -6.81 Million AUD | -11.96% |
| 2005 FY | -6.08 Million AUD | -185.28% |
| 2004 FY | -2.13 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -65.417% |
| Skye Bioscience, Inc. | -13.67 Million USD | 84.804% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.538% |
| Nascent Biotech, Inc. | -2.22 Million USD | 6.828% |
| Qrons Inc. | -643.67 Thousand USD | -222.776% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -400.057% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 58.814% |
| BioStem Technologies, Inc. | -7.77 Million USD | 73.292% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -202.443% |
| CSL Limited | 3.7 Billion USD | 100.056% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.257% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 88.359% |
| Rebus Holdings, Inc. | -664 Thousand USD | -212.896% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -55.578% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -433.314% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 86.908% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.106% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 142.273% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -693.819% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.26% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 27.114% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -35.258% |
| Mesoblast Limited | -84.14 Million USD | 97.531% |
| Marizyme, Inc. | -34.08 Million USD | 93.905% |
| Genus plc | 6.4 Million USD | 132.463% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 121.326% |
| Pharming Group N.V. | -4.87 Million USD | 57.422% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -4.589% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -123.07% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 75.118% |
| ContraFect Corporation | -56.88 Million USD | 96.348% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 54.385% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -48.192% |
| IMV Inc. | -38.67 Million USD | 94.627% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 24.473% |
| MultiCell Technologies, Inc. | -722.81 USD | -287338.193% |
| ONE Bio Corp. | 13.68 Million USD | 115.186% |
| Accustem Sciences Inc. | -3.74 Million USD | 44.544% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.478% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -330.096% |
| Q BioMed Inc. | -3.44 Million USD | 39.702% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 158.69% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 20.928% |
| Biomind Labs Inc. | -1 Million USD | -105.787% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.221% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 28.388% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 68.748% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -11.439% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -6836.538% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -7.504% |
| GB Sciences, Inc. | -1.42 Million USD | -46.26% |
| Alpha Cognition Inc. | -9.7 Million USD | 78.593% |
| HST Global, Inc. | -140.9 Thousand USD | -1374.47% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -84.694% |
| Halberd Corporation | -75.05 Thousand USD | -2668.33% |
| Enzolytics Inc. | -2.14 Million USD | 3.312% |
| Agentix Corp. | -1.37 Million USD | -51.458% |
| Resverlogix Corp. | -12.74 Million USD | 83.704% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 34.424% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.511% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -99.007% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 28.835% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -31.549% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 38.983% |
| AVAX Technologies, Inc. | 6.69 Million USD | 131.042% |
| Zenith Capital Corp. | -8.94 Million USD | 76.768% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.5% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -11826.02% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 15.382% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1111.38% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -3.635% |
| Kadimastem Ltd | -3.04 Million USD | 31.662% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -111.13% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1044.795% |
| LadRx Corporation | -3.82 Million USD | 45.663% |
| Cell Source, Inc. | -4.32 Million USD | 51.966% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -202.443% |
| NovAccess Global Inc. | -2.46 Million USD | 15.775% |
| Affymax, Inc. | -15.04 Million USD | 86.191% |
| Itoco Inc. | -919.14 Thousand USD | -126.041% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 50.981% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -85.669% |
| Mobile Lads Corp. | -554.55 Thousand USD | -274.652% |
| CytoDyn Inc. | -18.05 Million USD | 88.495% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -8154.398% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -844.043% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -267.903% |
| SYBLEU INC | -149.18 Thousand USD | -1292.701% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -14.387% |
| International Stem Cell Corporation | -663 Thousand USD | -213.368% |
| Bioxytran, Inc. | -3.82 Million USD | 45.614% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3846.869% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -10114.513% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.271% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -28.407% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -182.35% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 33.217% |
| Neutra Corp. | -229.48 Thousand USD | -805.342% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 88.154% |
| PureTech Health plc | -146.19 Million USD | 98.579% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 90.333% |
| IXICO plc | -1.43 Million USD | -44.581% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 78.109% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.294% |
| CSL Limited | 3.81 Billion USD | 100.055% |
| Cellectis S.A. | -108.85 Million USD | 98.091% |